<DOC>
	<DOCNO>NCT02432534</DOCNO>
	<brief_summary>Condition : Non segmental active vitiligo adulthood . Main objective : To evaluate efficacy daily treatment atorvastatin 80mg/d combine UVB compare UVB alone active vitiligo 6 month treatment . Methods : Prospective interventional bicentric study evaluation blind treatment receive . Inclusion criterion : Patients 18 75 year-old active non segmental vitiligo . Active define apparition modification vitiligo lesion past 3 month Wood 's lamp examination hypochromic border and/or spotty depigmentation . Interventions : After central randomization - Arm A : atorvastatin 40mg/d 1 month 80mg/d 5 month combine twice weekly narrowband UVB treatment 6 month . - Arm B : twice weekly narrowband UVB treatment 6 month . Evaluation : Main criterion : Decrease VASI score express percentage Secondary criterion : Decrease VETF score express percentage . Variation PGA DLQI score . Clinical biological tolerance . Variation CXCL10 level serum . Length study : Inclusion period : 12 month . Length treatment : 6 month . Statistical analysis draft article : 6 month . Total length : 24 month .</brief_summary>
	<brief_title>Atorvastatin Active Vitiligo</brief_title>
	<detailed_description />
	<mesh_term>Vitiligo</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Active nonsegmental vitiligo define Non segmental vitiligo new patch extension old lesion last 3 month AND Presence hypochromic aspect Wood 's lamp examination and/or perifollicular hypopigmentation Wood 's lamp examination Patient require treatment UVB Signed informed consent document Patient register French Social Security Segmental mix vitiligo Pregnant ( urinary pregnancy test do ) lactate patient Allergy statin medication Use statin fibrate medication due cardiac risk Use statin medication past 8 week Use medication contraindicate use statin medication Use vitiligo treatment ( topicals phototherapy ) past 4 week Treatment immunomodulating oral medication past 4 week Hepatic disease and/or dysfunction Renal dysfunction Personal familial history myopathy personal history rhabdomyolysis elevate baseline creatinine kinase Alcohol drug abuse Untreated hypothyroidism Personal history skin cancer Any clinically significant finding , opinion Principal Investigator , might interfere study evaluation pose risk subject safety study . Patients assess uncooperative Participants clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>